Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
IPO9 antisense RNA 1 (IPO9-AS1) is a human long non-coding RNA gene transcribed from the strand opposite to the IPO9 gene, which encodes a nuclear import protein. As a natural antisense transcript, IPO9-AS1 is thought to play a regulatory role in the expression of IPO9 or related genes via mechanisms common to antisense lncRNAs, such as modulation of chromatin structure or transcriptional interference. Long non-coding RNAs of this class are involved in regulation of gene expression but do not encode proteins. While many antisense RNAs have reported functions in various biological pathways and diseases, there is limited direct evidence implicating IPO9-AS1 as a therapeutic target or describing its specific biological or pathological implications. The gene is annotated under NCBI Gene ID: 100873949, Ensembl: ENSG00000231871, and HGNC: 40892.
Not applicable (There are no drugs known to target IPO9-AS1 directly; antisense RNAs in general can be targeted by antisense oligonucleotides for gene modulation, but this is not documented for IPO9-AS1 specifically)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on IPO9 antisense RNA 1 (IPO9-AS1).